FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2329050707> ?p ?o ?g. }

• W2329050707 endingPage "A73" @default.
• W2329050707 startingPage "A72.3" @default.
• W2329050707 abstract "<h3>Background</h3> Anti-TNF plus methotrexate (MTX) is more effective than either as monotherapy. Thus far, no controlled data are available on the benefit:risk of different doses of MTX in combination with anti-TNF. <h3>Objectives</h3> To determine the effect of MTX dose in combination with adalimumab (ADA) on efficacy, pharmacokinetics, and safety in patients (pts) with early rheumatoid arthritis (RA). <h3>Methods</h3> CONCERTO was a 26-week (wk), double-blind, parallel-arm trial in MTX and biologic-naive pts with active RA [DAS28(CRP) ≥3.2; CRP ≥1.5 mg/dL or ESR ≥28 mm/hr; ≥1 erosion or RF+ or ACPA+] of <1 year duration. Pts were randomized 1:1:1:1 to wkly oral MTX (2.5, 5, 10, or 20 mg) and received open-label (OL) ADA 40 mg every other wk (eow). Pts in the 20 mg arm began 10 mg and escalated 2.5 mg eow to 20 mg. The primary endpoint was the achievement of low disease activity [LDA, DAS28(CRP) <3.2] at wk 26. Secondary endpoints included ACR50/70/90, DAS28(CRP) (<2.6)/SDAI (≤3.3)/CDAI (≤2.8) remission, radiographic nonprogression (ΔmTSS ≤0.5), and ΔHAQ-DI ≤-0.22 at wk 26. Dose-response was assessed via Cochran-Armitage linear trend test. Non-responder imputation was used for missing data. Serum samples for pharmacokinetics were collected prior to baseline and at all study visits. Safety was assessed in terms of adverse events (AEs) for all pts who received ≥1 dose of study drug. <h3>Results</h3> Of the 395 randomized pts, 358 (83, 93, 93, and 89 from the 2.5, 5, 10, and 20 mg arms, respectively) completed 26 wks. At wk 26, there was a statistically significant trend in the proportion of pts achieving LDA with increasing dose of MTX in combination with OL ADA (<b>Table</b>). Significant trends were noted as early as wk 12 and sustained through wk 26. Similar results were observed for ACR50/70/90 and DAS28(CRP)/SDAI/CDAI remission. Numerically increasing trends were also apparent in the proportions achieving radiographic nonprogression and ΔHAQ-DI ≤-0.22 at wk 26. Clinical and radiographic outcomes generally appeared comparable between the 10 and 20 mg arms. ADA serum concentrations were similar in the 10 and 20 mg MTX arms, with slightly lower mean ADA serum concentrations in the 2.5 and 5 mg arms. AEs were consistent with the known profile of anti-TNF and were generally consistent between arms, occurring most frequently in the 20 mg arm. <h3>Conclusions</h3> MTX and biologic-naïve pts with early RA demonstrated robust and dose-dependent clinical responses with increasing doses of MTX in combination with OL ADA through 26 wks. Interestingly, clinical responses and ADA serum concentrations generally appeared similar between the 10 and 20 mg MTX arms. <h3>Acknowledgements</h3> AbbVie Inc. sponsored the study (NCT01185301), contributed to its design, and participated in the collection, analysis, and interpretation of the data, and in the writing, reviewing, and approval of the final version. Medical writing support was provided by Benjamin Wolfe, PhD, of AbbVie Inc. <h3>Disclosure of Interest</h3> G. Burmester Grant/research support from: AbbVie Inc., BMS, Merck, Roche, Pfizer, UCB, Consultant for: AbbVie Inc., BMS, Merck, Roche, Pfizer, UCB, Speakers bureau: AbbVie Inc., BMS, Merck, Roche, Pfizer, UCB, A. Kivitz Grant/research support from: AbbVie Inc., Pfizer, Genentech, UCB, Amgen, Celgene, BMS, Astra-Zeneca, Janssen, Consultant for: Genentech, UCB, BMS, Speakers bureau: BMS, H. Kupper Shareholder of: AbbVie Inc., Employee of: AbbVie Inc., U. Arulmani Shareholder of: AbbVie Inc., Employee of: AbbVie Inc., S. Florentinus Shareholder of: AbbVie Inc., Employee of: AbbVie Inc., S. Goss Shareholder of: AbbVie Inc., Employee of: AbbVie Inc., S. Rathmann Shareholder of: AbbVie Inc., Employee of: AbbVie Inc., R. Fleischmann Grant/research support from: AbbVie Inc., Pfizer, Merck, Roche, UCB, Celgene, Amgen, Astra-Zeneca, BMS, Janssen, Lilly, Novartis, Consultant for: AbbVie Inc., Pfizer, Merck, Roche, UCB, Celgene, Amgen, Astra-Zeneca, BMS, Janssen, Lilly, Novartis" @default.
• W2329050707 created "2016-06-24" @default.
• W2329050707 creator A5014521677 @default.
• W2329050707 creator A5030598737 @default.
• W2329050707 creator A5046261111 @default.
• W2329050707 creator A5073833664 @default.
• W2329050707 creator A5079625006 @default.
• W2329050707 creator A5082669130 @default.
• W2329050707 creator A5090992937 @default.
• W2329050707 creator A5091037280 @default.
• W2329050707 date "2013-06-01" @default.
• W2329050707 modified "2023-10-03" @default.
• W2329050707 title "OP0067 Efficacy, Pharmacokinetics, and Safety of Different Doses of Methotrexate in Combination with Adalimumab: Results from the Concerto Trial" @default.
• W2329050707 doi "https://doi.org/10.1136/annrheumdis-2013-eular.272" @default.
• W2329050707 hasPublicationYear "2013" @default.
• W2329050707 type Work @default.
• W2329050707 sameAs 2329050707 @default.
• W2329050707 citedByCount "4" @default.
• W2329050707 countsByYear W23290507072013 @default.
• W2329050707 countsByYear W23290507072014 @default.
• W2329050707 crossrefType "journal-article" @default.
• W2329050707 hasAuthorship W2329050707A5014521677 @default.
• W2329050707 hasAuthorship W2329050707A5030598737 @default.
• W2329050707 hasAuthorship W2329050707A5046261111 @default.
• W2329050707 hasAuthorship W2329050707A5073833664 @default.
• W2329050707 hasAuthorship W2329050707A5079625006 @default.
• W2329050707 hasAuthorship W2329050707A5082669130 @default.
• W2329050707 hasAuthorship W2329050707A5090992937 @default.
• W2329050707 hasAuthorship W2329050707A5091037280 @default.
• W2329050707 hasConcept C112705442 @default.
• W2329050707 hasConcept C126322002 @default.
• W2329050707 hasConcept C141071460 @default.
• W2329050707 hasConcept C2777226972 @default.
• W2329050707 hasConcept C2777575956 @default.
• W2329050707 hasConcept C2779722408 @default.
• W2329050707 hasConcept C2780132546 @default.
• W2329050707 hasConcept C2781059491 @default.
• W2329050707 hasConcept C71924100 @default.
• W2329050707 hasConcept C90924648 @default.
• W2329050707 hasConceptScore W2329050707C112705442 @default.
• W2329050707 hasConceptScore W2329050707C126322002 @default.
• W2329050707 hasConceptScore W2329050707C141071460 @default.
• W2329050707 hasConceptScore W2329050707C2777226972 @default.
• W2329050707 hasConceptScore W2329050707C2777575956 @default.
• W2329050707 hasConceptScore W2329050707C2779722408 @default.
• W2329050707 hasConceptScore W2329050707C2780132546 @default.
• W2329050707 hasConceptScore W2329050707C2781059491 @default.
• W2329050707 hasConceptScore W2329050707C71924100 @default.
• W2329050707 hasConceptScore W2329050707C90924648 @default.
• W2329050707 hasIssue "Suppl 3" @default.
• W2329050707 hasLocation W23290507071 @default.
• W2329050707 hasOpenAccess W2329050707 @default.
• W2329050707 hasPrimaryLocation W23290507071 @default.
• W2329050707 hasRelatedWork W2009656202 @default.
• W2329050707 hasRelatedWork W2043008431 @default.
• W2329050707 hasRelatedWork W2314299446 @default.
• W2329050707 hasRelatedWork W2319798934 @default.
• W2329050707 hasRelatedWork W2332601515 @default.
• W2329050707 hasRelatedWork W2333864817 @default.
• W2329050707 hasRelatedWork W2748864731 @default.
• W2329050707 hasRelatedWork W2807883977 @default.
• W2329050707 hasRelatedWork W2808567002 @default.
• W2329050707 hasRelatedWork W2891260950 @default.
• W2329050707 hasRelatedWork W2899376345 @default.
• W2329050707 hasRelatedWork W2947887453 @default.
• W2329050707 hasRelatedWork W2950207837 @default.
• W2329050707 hasRelatedWork W3033912793 @default.
• W2329050707 hasRelatedWork W3034156099 @default.
• W2329050707 hasRelatedWork W3034621686 @default.
• W2329050707 hasRelatedWork W3041714706 @default.
• W2329050707 hasRelatedWork W3048126481 @default.
• W2329050707 hasRelatedWork W3124239507 @default.
• W2329050707 hasRelatedWork W3164886424 @default.
• W2329050707 hasVolume "72" @default.
• W2329050707 isParatext "false" @default.
• W2329050707 isRetracted "false" @default.
• W2329050707 magId "2329050707" @default.
• W2329050707 workType "article" @default.